In fiscal 2025, which ended Dec 31, 2025, Niagen Bioscience, Inc. reported revenue of $129.4 million, up 29.9% from the year before. Net income was $17.4 million, a profit margin of 13.4%. Operating income came to $16.3 million, an operating margin of 12.6%. Diluted earnings per share were $0.20. Over the twelve months ended Sep 30, 2026, revenue was $122.3 million and net income was $10.2 million. Across the 8 fiscal years shown, revenue grew from $31.6 million in fiscal 2018 to $129.4 million in fiscal 2025, about 22.3% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 30, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
122
-1.9%
|
129
+29.9%
|
100
+19.2%
|
84
+16.0%
|
72
+6.8%
|
67
+13.8%
|
59
+28.0%
|
46
+46.7%
|
32
|
—
|
—
|
| Cost of revenue |
44
-1.9%
|
46
+21.6%
|
38
+15.9%
|
33
+12.1%
|
29
+12.7%
|
26
+8.2%
|
24
+16.9%
|
21
+32.4%
|
16
+44.6%
|
11
-4.9%
|
11
+8.9%
|
| Gross profit |
78
-2.0%
|
83
+35.1%
|
62
+21.3%
|
51
+18.7%
|
43
+3.2%
|
41
+17.6%
|
35
+36.9%
|
26
+60.5%
|
16
+53.2%
|
10
+0.8%
|
10
+37.9%
|
| Research and development |
6
+9.5%
|
6
+5.2%
|
6
+21.3%
|
5
+2.7%
|
5
+25.9%
|
4
+12.2%
|
3
-22.7%
|
4
-19.3%
|
5
+36.7%
|
4
+58.8%
|
3
+182.9%
|
| Selling, general and administrative |
69
+26.4%
|
63
+30.8%
|
48
-7.0%
|
51
-9.1%
|
57
-12.6%
|
65
+25.2%
|
52
-1.5%
|
53
+20.3%
|
44
+97.6%
|
22
+105.2%
|
11
+23.7%
|
| Operating income |
5
-75.3%
|
16
+110.7%
|
8
+238.0%
|
-6
+69.9%
|
-19
+31.2%
|
-27
-36.4%
|
-20
+36.6%
|
-31
+5.6%
|
-33
-102.6%
|
-16
-463.7%
|
-3
-40.6%
|
| Pretax income |
11
|
18
+105.4%
|
9
|
—
|
—
|
—
|
—
|
—
|
—
|
-17
-365.4%
|
-4
-34.9%
|
| Income tax |
1
|
1
+165.6%
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
0
|
0
+100.0%
|
| Net income |
10
-49.9%
|
17
+103.3%
|
9
+273.1%
|
-5
+70.1%
|
-17
+39.0%
|
-27
-36.2%
|
-20
+38.0%
|
-32
+3.5%
|
-33
-192.8%
|
-11
-288.6%
|
-3
-5.7%
|
| Basic EPS |
0.13
-50.6%
|
0.22
+100.0%
|
0.11
+257.1%
|
-0.07
+70.8%
|
-0.24
+40.0%
|
-0.40
|
—
|
—
|
—
|
—
|
—
|
| Diluted EPS |
0.12
-49.2%
|
0.20
+81.8%
|
0.11
+257.1%
|
-0.07
+70.8%
|
-0.24
+40.0%
|
-0.40
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, basic |
80
+1.4%
|
79
+4.3%
|
76
+1.3%
|
75
+7.5%
|
70
+3.8%
|
67
|
—
|
—
|
—
|
—
|
37
+3.9%
|
| Weighted average shares, diluted |
83
-1.4%
|
85
+9.4%
|
78
+4.2%
|
75
+7.5%
|
70
+3.8%
|
67
|
—
|
—
|
—
|
—
|
—
|
| Other measures | |||||||||||
| Depreciation and amortization |
0
-22.0%
|
1
-7.7%
|
1
-23.8%
|
1
+0.1%
|
1
-2.4%
|
1
+2.2%
|
1
+14.3%
|
1
+25.5%
|
1
+19.0%
|
1
+53.7%
|
0
+16.2%
|
| EBITDA |
5
-73.6%
|
17
+101.3%
|
8
+277.4%
|
-5
+73.4%
|
-18
+32.2%
|
-26
-37.9%
|
-19
+37.8%
|
-31
+6.2%
|
-33
-105.2%
|
-16
-516.6%
|
-3
-44.5%
|
| Interest coverage |
—
|
—
|
—
|
—
|
—
|
-492.24x
|
-279.63x
|
-36.95x
|
-419.90x
|
-107.04x
|
-8.72x
|
| Margins | |||||||||||
| Gross margin |
63.86%
|
64.28%
|
61.84%
|
60.76%
|
59.40%
|
61.51%
|
59.53%
|
55.67%
|
50.88%
|
—
|
—
|
| Operating margin |
3.90%
|
12.58%
|
7.76%
|
-6.70%
|
-25.85%
|
-40.14%
|
-33.50%
|
-67.62%
|
-105.12%
|
—
|
—
|
| Pretax margin |
9.04%
|
14.06%
|
8.89%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Profit margin |
8.37%
|
13.43%
|
8.58%
|
-5.91%
|
-22.96%
|
-40.22%
|
-33.62%
|
-69.45%
|
-105.57%
|
—
|
—
|
| EBITDA margin |
4.30%
|
13.05%
|
8.42%
|
-5.66%
|
-24.65%
|
-38.82%
|
-32.04%
|
-65.97%
|
-103.19%
|
—
|
—
|
| Effective tax rate |
7.37%
|
4.45%
|
3.44%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- NAGE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1386570
- Former names
- ChromaDex Corp. (until Mar 10, 2025); CODY RESOURCES, INC. (until Jun 24, 2008)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.